Healthcare / Medical Instruments & SuppliesTokyo
$3055.00
+5.00 (+0.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $10.0B · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$253.7B
P/E
N/A
•EV/EBITDA
23.8x
↑ROE
-2.1%
↓Gross Margin
56.7%
↑Debt/Equity
0.23
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.6%
FCF CAGR
+44.2%
FCF margin
14.0%
FCF / Net income
-4.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $81.18B · net income $-2.40B · FCF $11.34B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $81.18B | $81.18B | $77.04B | $59.69B | $48.67B |
| Net Income | $-2.40B | $-2.40B | $8.58B | $22.80B | $12.47B |
| EBITDA | $9.29B | $9.29B | $19.59B | $32.27B | $19.40B |
| EPS | -28.70 | -28.70 | 101.06 | 266.87 | 145.11 |
| Gross Margin | 56.7% | 56.7% | 57.7% | 60.5% | 64.1% |
| Operating Margin | 17.4% | 17.4% | 18.9% | 23.9% | 31.6% |
| Net Margin | -3.0% | -3.0% | 11.1% | 38.2% | 25.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.23 | 0.23 | 0.15 | 0.10 | 0.01 |
| Current Ratio | 3.07 | 3.07 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $11.34B | $11.34B | $10.05B | $2.60B | $3.78B |
| Returns | |||||
| ROE | -2.1% | -2.1% | 7.1% | 20.1% | 13.7% |
| Valuation | |||||
| P/E | — | — | 23.69 | 9.06 | 17.56 |
| EV/EBITDA | 23.76 | 23.76 | 8.98 | 5.78 | 9.51 |
| P/B | 2.24 | 2.24 | 1.68 | 1.83 | 2.41 |
| Growth & Yield | |||||
| Revenue Growth | 5.4% | 5.4% | 29.1% | 22.6% | — |
| EPS Growth | -128.4% | -128.4% | -62.1% | 83.9% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+65.9%
Start / end P/E
n/dx → n/dx
EPS bridge
101.06 → -28.70
Residual
+63.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.